New combo therapy offers hope for ITP patients who failed steroids

NCT ID NCT07234019

First seen Nov 18, 2025 · Last updated Jun 12, 2026 · Updated 26 times

Summary

This study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) who did not improve or relapsed after steroid treatment. About 160 participants will receive either the combination or rituximab alone. The main goal is to see if more patients achieve a safe platelet count by week 12 without needing rescue therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese Academy of Medical Science and Blood Disease Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.